title: Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration.
abstract: BACKGROUND
  To investigate the effects of intravitreal bevacizumab on retrobulbar circulation in patients with neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Thirty patients with neovascular age-related macular degeneration were assessed prospectively by both color Doppler imaging and fundus fluorescein angiography. Spectral Doppler analysis allowed the measurement of the maximum velocity (Vmax) and minimum velocity (Vmin) of the central retinal vein (CRV), and peak systolic (PSV), end-diastolic (EDV) velocities of blood flows, and pulsatility index (PI) and resistance index (RI) values in the central retinal artery (CRA), nasal and temporal posterior ciliary arteries (NPCA, TPCA), and ophthalmic artery (OA). The t test for paired samples was used to compare retrobulbar blood flow values before and after intravitreal bevacizumab injection.
  
  
  RESULTS
  PSV and EDV of the NPCA and PSV of the TPCA were significantly decreased after intravitreal bevacizumab injection (p < 0.05). There was no statistically significant difference in the other parameters.
  
  
  CONCLUSIONS
  Our results suggest that intravitreal bevacizumab therapy has a measurable effect on retrobulbar blood flow.
authors: Gaziantep University Medical School, Department of Radiology, Sahinbey, Gaziantep, Turkey.
authors: Ahmet
authors: A
authors: Mete
authors: Oguzhan
authors: O
authors: Saygili
authors: Alper
authors: A
authors: Mete
authors: Metin
authors: M
authors: Bayram
authors: Necdet
authors: N
authors: Bekir
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001783:Blood Flow Velocity / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009880:Ophthalmic Artery / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011446:Prospective Studies; D012039:Regional Blood Flow / Q000187:drug effects* / Q000502:physiology; D012161:Retinal Artery / Q000000981:diagnostic imaging / Q000503:physiopathology; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012169:Retinal Vein / Q000000981:diagnostic imaging / Q000503:physiopathology; D016896:Treatment Outcome; D018615:Ultrasonography, Doppler, Color / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab